3-N-Butylphthalide
Tipranavir may increase the antiplatelet activities of Butylphthalide.
Abacavir
The serum concentration of Abacavir can be decreased when it is combined with Tipranavir.
Abciximab
Tipranavir may increase the anticoagulant activities of Abciximab.
Advertisement
Abiraterone
The serum concentration of Tipranavir can be increased when it is combined with Abiraterone.
Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Tipranavir.
Acenocoumarol
Tipranavir may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Tipranavir.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tipranavir.
Acetyl salicylate
Tipranavir may increase the antiplatelet activities of Acetylsalicylic acid.
Advertisement
Acetylcholine
The metabolism of Acetylcholine can be decreased when combined with Tipranavir.
Acetylcholine Chloride
The metabolism of Acetylcholine can be decreased when combined with Tipranavir.
Ajmaline
The metabolism of Ajmaline can be decreased when combined with Tipranavir.
Alfuzosin
The serum concentration of Alfuzosin can be increased when it is combined with Tipranavir.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Tipranavir.
Alogliptin
The serum concentration of Alogliptin can be decreased when it is combined with Tipranavir.
alpha 1-Antitrypsin
The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Tipranavir.
Alpha 1-Proteinase Inhibitor, Human
The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Tipranavir.
alpha Tocopherol
The risk or severity of adverse effects can be increased when Tipranavir is combined with Vitamin E.
Alprazolam
The serum concentration of Alprazolam can be increased when it is combined with Tipranavir.
Alprenolol
The metabolism of Alprenolol can be decreased when combined with Tipranavir.
Alprostadil
Tipranavir may increase the antiplatelet activities of Alprostadil.
AMBROXOL ACEFYLLINATE
The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Tipranavir.
Ambroxol-Theophylline-7-Acetate
The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Tipranavir.
Amineptin
The serum concentration of Amineptine can be increased when it is combined with Tipranavir.
Aminophylline
The serum concentration of Aminophylline can be decreased when it is combined with Tipranavir.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Tipranavir.
Amiodarone
The serum concentration of Amiodarone can be increased when it is combined with Tipranavir.
Amitriptyline
The metabolism of Amitriptyline can be decreased when combined with Tipranavir.
Amoxapine
The metabolism of Amoxapine can be decreased when combined with Tipranavir.
Amphetamine
The metabolism of Amphetamine can be decreased when combined with Tipranavir.
Amprenavir
The serum concentration of Amprenavir can be decreased when it is combined with Tipranavir.
Amsacrine
The metabolism of Amsacrine can be decreased when combined with Tipranavir.
Anagrelide
Tipranavir may increase the antiplatelet activities of Anagrelide.
Ancrod
Tipranavir may increase the anticoagulant activities of Ancrod.
Anhydrous Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Tipranavir.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Tipranavir.
Antithrombin III
The serum concentration of Antithrombin III human can be decreased when it is combined with Tipranavir.
Antithrombin III, Human
The serum concentration of Antithrombin III human can be decreased when it is combined with Tipranavir.
Apalutamide
The serum concentration of Tipranavir can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Apixaban can be decreased when it is combined with Tipranavir.
Aprepitant
The serum concentration of Tipranavir can be increased when it is combined with Aprepitant.
Aprindine
The metabolism of Aprindine can be decreased when combined with Tipranavir.
Aprotinin
The serum concentration of Aprotinin can be decreased when it is combined with Tipranavir.
Ardeparin
Tipranavir may increase the anticoagulant activities of Ardeparin.
Arformoterol
The metabolism of Arformoterol can be decreased when combined with Tipranavir.
Argatroban
Tipranavir may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Tipranavir may increase the anticoagulant activities of Argatroban.
Aripiprazole
The serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.
Armodafinil
The metabolism of Tipranavir can be decreased when combined with Armodafinil.
Artemether
The metabolism of Artemether can be decreased when combined with Tipranavir.
Aspirin
Tipranavir may increase the antiplatelet activities of Acetylsalicylic acid.
Astemizole
The metabolism of Astemizole can be decreased when combined with Tipranavir.
Asunaprevir
The serum concentration of Asunaprevir can be decreased when it is combined with Tipranavir.
Atazanavir
The serum concentration of Atazanavir can be decreased when it is combined with Tipranavir.
Atomoxetine
The serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.
Atorvastatin
The serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.
Azelastine
Tipranavir may increase the antiplatelet activities of Azelastine.
Becaplermin
Tipranavir may increase the anticoagulant activities of Becaplermin.
Benazepril
The serum concentration of Benazepril can be decreased when it is combined with Tipranavir.
Benztropine
The metabolism of Benzatropine can be decreased when combined with Tipranavir.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Tipranavir.
Bepridil
The serum concentration of Bepridil can be increased when it is combined with Tipranavir.
Betaxolol
The metabolism of Betaxolol can be decreased when combined with Tipranavir.
Bisoprolol
The metabolism of Bisoprolol can be decreased when combined with Tipranavir.
Bivalirudin
Tipranavir may increase the anticoagulant activities of Bivalirudin.
Boceprevir
The serum concentration of Boceprevir can be decreased when it is combined with Tipranavir.
Bortezomib
The metabolism of Bortezomib can be decreased when combined with Tipranavir.
Bosentan
The serum concentration of Tipranavir can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Tipranavir.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Tipranavir.
Brexpiprazole
The serum concentration of Brexpiprazole can be increased when it is combined with Tipranavir.
Bromocriptine
The serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.
Brompheniramine
The metabolism of Brompheniramine can be decreased when combined with Tipranavir.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Tipranavir.
Buprenorphine
The metabolism of Buprenorphine can be decreased when combined with Tipranavir.
Bupropion
The metabolism of Tipranavir can be decreased when combined with Bupropion.
Buspirone
The metabolism of Buspirone can be decreased when combined with Tipranavir.
Cabergoline
The serum concentration of Cabergoline can be increased when it is combined with Tipranavir.
Caffeine
The metabolism of Caffeine can be decreased when combined with Tipranavir.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.
Cangrelor
Tipranavir may increase the antiplatelet activities of Cangrelor.
Captopril
The serum concentration of Captopril can be decreased when it is combined with Tipranavir.
Carbamazepine
The metabolism of Tipranavir can be increased when combined with Carbamazepine.
Cariprazine
The metabolism of Cariprazine can be decreased when combined with Tipranavir.
Carteolol
The metabolism of Carteolol can be decreased when combined with Tipranavir.
Carvedilol
The metabolism of Carvedilol can be decreased when combined with Tipranavir.
Celecoxib
The metabolism of Tipranavir can be decreased when combined with Celecoxib.
Cephalexin
The metabolism of Cephalexin can be decreased when combined with Tipranavir.
CEPHALEXIN ANHYDROUS
The metabolism of Cephalexin can be decreased when combined with Tipranavir.
Ceritinib
The serum concentration of Tipranavir can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Tipranavir.
Certoparin
Tipranavir may increase the anticoagulant activities of Certoparin.
Cevimeline
The metabolism of Cevimeline can be decreased when combined with Tipranavir.
Chloramphenicol
The metabolism of Tipranavir can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The metabolism of Chlordiazepoxide can be decreased when combined with Tipranavir.
Chloroquine
The metabolism of Chloroquine can be decreased when combined with Tipranavir.
Chlorotrianisene
Chlorotrianisene may increase the dermatologic adverse activities of Tipranavir.
Chlorpheniramine
The metabolism of Chlorphenamine can be decreased when combined with Tipranavir.
CHLORPHENIRAMINE POLISTIREX
The metabolism of Chlorphenamine can be decreased when combined with Tipranavir.
Chlorpromazine
The metabolism of Chlorpromazine can be decreased when combined with Tipranavir.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tipranavir.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Tipranavir.
Cholecalciferol
The metabolism of Tipranavir can be decreased when combined with Cholecalciferol.
Cholesterol
The serum concentration of Cholesterol can be decreased when it is combined with Tipranavir.
Cilastatin
The serum concentration of Cilastatin can be decreased when it is combined with Tipranavir.
Cilazapril
The serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Tipranavir.
Cimetidine
The metabolism of Tipranavir can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Tipranavir can be decreased when combined with Cinacalcet.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Tipranavir.
Citalopram
The metabolism of Citalopram can be decreased when combined with Tipranavir.
Citric Acid
Tipranavir may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Tipranavir may increase the anticoagulant activities of Citric Acid.
Clarithromycin
The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Tipranavir.
Clemastine
The metabolism of Tipranavir can be decreased when combined with Clemastine.
Clevidipine
The metabolism of Clevidipine can be decreased when combined with Tipranavir.
Clevidipine butyrate
The metabolism of Clevidipine can be decreased when combined with Tipranavir.
Clobazam
The metabolism of Tipranavir can be decreased when combined with Clobazam.
Clofezone
The serum concentration of Rabeprazole can be decreased when it is combined with Tipranavir.
Clomipramine
The metabolism of Clomipramine can be decreased when combined with Tipranavir.
Clonidine
The metabolism of Clonidine can be decreased when combined with Tipranavir.
Clopidogrel
Tipranavir may increase the antiplatelet activities of Clopidogrel.
Clotrimazole
The metabolism of Tipranavir can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Clozapine can be decreased when combined with Tipranavir.
Cobicistat
The serum concentration of Tipranavir can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Tipranavir can be decreased when combined with Cocaine.
Codeine
The therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.
Codeine Anhydrous
The therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.
CODEINE POLISTIREX
The therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Tipranavir.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Tipranavir.
Crizotinib
The metabolism of Tipranavir can be decreased when combined with Crizotinib.
Cyclobenzaprine
The metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.
Cyclosporine
The serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.
Dabigatran Etexilate
The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir.
Dabrafenib
The serum concentration of Tipranavir can be decreased when it is combined with Dabrafenib.
Dalteparin
Tipranavir may increase the anticoagulant activities of Dalteparin.
Danaparoid
Tipranavir may increase the anticoagulant activities of Danaparoid.
Dapagliflozin
The metabolism of Dapagliflozin can be decreased when combined with Tipranavir.
Darifenacin
The metabolism of Darifenacin can be decreased when combined with Tipranavir.
Darunavir
The serum concentration of Darunavir can be decreased when it is combined with Tipranavir.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Tipranavir.
Dasatinib
The serum concentration of Tipranavir can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Tipranavir can be increased when it is combined with Dasatinib.
Debrisoquin
The metabolism of Debrisoquin can be decreased when combined with Tipranavir.
Deferasirox
The serum concentration of Tipranavir can be decreased when it is combined with Deferasirox.
Defibrotide
Tipranavir may increase the antiplatelet activities of Defibrotide.
Delavirdine
The serum concentration of Delavirdine can be decreased when it is combined with Tipranavir.
Desipramine
The metabolism of Desipramine can be decreased when combined with Tipranavir.
Desirudin
Tipranavir may increase the anticoagulant activities of Desirudin.
Desogestrel
The serum concentration of Desogestrel can be increased when it is combined with Tipranavir.
Deutetrabenazine
The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Tipranavir.
Dexchlorpheniramine maleate
The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Tipranavir.
Dexfenfluramine
The metabolism of Dexfenfluramine can be decreased when combined with Tipranavir.
Dexlansoprazole
The serum concentration of Dexlansoprazole can be decreased when it is combined with Tipranavir.
Dexmethylphenidate
The metabolism of Dexmethylphenidate can be decreased when combined with Tipranavir.
Dextran
Tipranavir may increase the anticoagulant activities of Dextran.
Dextran 40
Tipranavir may increase the anticoagulant activities of Dextran 40.
Dextran 70
Tipranavir may increase the anticoagulant activities of Dextran 70.
Dextran 75
Tipranavir may increase the anticoagulant activities of Dextran 75.
Dextroamphetamine
The metabolism of Dextroamphetamine can be decreased when combined with Tipranavir.
Dextromethorphan
The metabolism of Dextromethorphan can be decreased when combined with Tipranavir.
Dicumarol
Tipranavir may increase the anticoagulant activities of Dicoumarol.
Didanosine
The serum concentration of Didanosine can be decreased when it is combined with Tipranavir.
Dienestrol
Dienestrol may increase the dermatologic adverse activities of Tipranavir.
Dienogest
The serum concentration of Dienogest can be increased when it is combined with Tipranavir.
Diethylstilbestrol
Diethylstilbestrol may increase the dermatologic adverse activities of Tipranavir.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Tipranavir.
Dihydrocodeine
The metabolism of Dihydrocodeine can be decreased when combined with Tipranavir.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tipranavir.
Diltiazem
The metabolism of Diltiazem can be decreased when combined with Tipranavir.
Diphenhydramine
The metabolism of Diphenhydramine can be decreased when combined with Tipranavir.
Dipyridamole
Tipranavir may increase the antiplatelet activities of Dipyridamole.
Disulfiram
The risk or severity of adverse effects can be increased when Disulfiram is combined with Tipranavir.
Dolasetron
The metabolism of Dolasetron can be decreased when combined with Tipranavir.
Dolutegravir
The serum concentration of Dolutegravir can be decreased when it is combined with Tipranavir.
Domperidone
The metabolism of Domperidone can be decreased when combined with Tipranavir.
Donepezil
The metabolism of Donepezil can be decreased when combined with Tipranavir.
Dopamine
The metabolism of Dopamine can be decreased when combined with Tipranavir.
Dothiepin
The metabolism of Tipranavir can be decreased when combined with Dosulepin.
Doxazosin
The metabolism of Doxazosin can be decreased when combined with Tipranavir.
Doxepin
The metabolism of Doxepin can be decreased when combined with Tipranavir.
Doxorubicin
The metabolism of Doxorubicin can be decreased when combined with Tipranavir.
Doxorubicin Hydrochloride
The metabolism of Doxorubicin can be decreased when combined with Tipranavir.
Doxycycline
The metabolism of Tipranavir can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Tipranavir can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Dronedarone can be decreased when combined with Tipranavir.
Drospirenone
The serum concentration of Drospirenone can be increased when it is combined with Tipranavir.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tipranavir.
Duloxetine
The serum concentration of Duloxetine can be increased when it is combined with Tipranavir.
Dyphylline
The serum concentration of Dyphylline can be decreased when it is combined with Tipranavir.
Edetic Acid
Tipranavir may increase the anticoagulant activities of Edetic Acid.
Edoxaban
The serum concentration of Edoxaban can be decreased when it is combined with Tipranavir.
Efavirenz
The metabolism of Tipranavir can be decreased when combined with Efavirenz.
Eletriptan
The metabolism of Eletriptan can be decreased when combined with Tipranavir.
Eliglustat
The serum concentration of Eliglustat can be increased when it is combined with Tipranavir.
Eluxadoline
The serum concentration of Eluxadoline can be increased when it is combined with Tipranavir.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.
Enalapril
The serum concentration of Enalapril can be decreased when it is combined with Tipranavir.
Enalaprilat
The serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir.
Enalaprilat Anhydrous
The serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Tipranavir.
Encainide
The metabolism of Encainide can be decreased when combined with Tipranavir.
Enfuvirtide
The serum concentration of Enfuvirtide can be increased when it is combined with Tipranavir.
Enoxaparin
Tipranavir may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Tipranavir may increase the anticoagulant activities of Enoxaparin.
Enzalutamide
The serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide.
Epigallocatechin Gallate
The serum concentration of Epigallocatechin Gallate can be decreased when it is combined with Tipranavir.
Epinastine
Tipranavir may increase the antiplatelet activities of Epinastine.
Epoprostenol
Tipranavir may increase the antiplatelet activities of Epoprostenol.
Eptifibatide
Tipranavir may increase the antiplatelet activities of Eptifibatide.
Equol, (-)-
Equol may increase the dermatologic adverse activities of Tipranavir.
ergoloid mesylates, USP
The serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Tipranavir.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Tipranavir.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Tipranavir.
Erythromycin
The metabolism of Tipranavir can be decreased when combined with Erythromycin.
Escitalopram
The metabolism of Escitalopram can be decreased when combined with Tipranavir.
Eslicarbazepine Acetate
The metabolism of Tipranavir can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The serum concentration of Esomeprazole can be decreased when it is combined with Tipranavir.
Estradiol
Estradiol may increase the dermatologic adverse activities of Tipranavir.
Estradiol acetate
Estradiol acetate may increase the dermatologic adverse activities of Tipranavir.
Estradiol Cypionate
Estradiol cypionate may increase the dermatologic adverse activities of Tipranavir.
Estradiol Valerate
Estradiol valerate may increase the dermatologic adverse activities of Tipranavir.
Estramustine
The serum concentration of Estramustine can be decreased when it is combined with Tipranavir.
Estriol
Estriol may increase the dermatologic adverse activities of Tipranavir.
Estrogens, Conjugated (USP)
Conjugated estrogens may increase the dermatologic adverse activities of Tipranavir.
Estrogens, Esterified (USP)
Estrogens, esterified may increase the dermatologic adverse activities of Tipranavir.
Estrone
Estrone may increase the dermatologic adverse activities of Tipranavir.
Ethinyl Estradiol
Ethinyl Estradiol may increase the dermatologic adverse activities of Tipranavir.
Ethylenediaminetetraacetate
Tipranavir may increase the anticoagulant activities of Edetic Acid.
Ethylmorphine
The metabolism of Ethylmorphine can be decreased when combined with Tipranavir.
Ethynodiol Diacetate
The serum concentration of Ethynodiol diacetate can be increased when it is combined with Tipranavir.
Etonogestrel
The serum concentration of Etonogestrel can be increased when it is combined with Tipranavir.
Etoricoxib
The metabolism of Etoricoxib can be decreased when combined with Tipranavir.
Etravirine
The serum concentration of Etravirine can be decreased when it is combined with Tipranavir.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Tipranavir.
Ferulic Acid
Tipranavir may increase the anticoagulant activities of Ferulic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.
Fibrinolysis Inhibitor
The serum concentration of Aprotinin can be decreased when it is combined with Tipranavir.
Fingolimod
The metabolism of Fingolimod can be decreased when combined with Tipranavir.
Flecainide
The serum concentration of Flecainide can be increased when it is combined with Tipranavir.
Fluconazole
The serum concentration of Tipranavir can be increased when it is combined with Fluconazole.
Fluindione
Tipranavir may increase the anticoagulant activities of Fluindione.
Flunarizine
The metabolism of Flunarizine can be decreased when combined with Tipranavir.
Fluoxetine
The metabolism of Tipranavir can be decreased when combined with Fluoxetine.
Fluphenazine
The metabolism of Fluphenazine can be decreased when combined with Tipranavir.
Fluticasone propionate
The serum concentration of Fluticasone propionate can be increased when it is combined with Tipranavir.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Tipranavir.
Fluvoxamine
The metabolism of Tipranavir can be decreased when combined with Fluvoxamine.
Fondaparinux
Tipranavir may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Tipranavir may increase the anticoagulant activities of Fondaparinux sodium.
Formoterol
The metabolism of Formoterol can be decreased when combined with Tipranavir.
Fosamprenavir
The serum concentration of Fosamprenavir can be decreased when it is combined with Tipranavir.
Fosaprepitant
The serum concentration of Tipranavir can be increased when it is combined with Fosaprepitant.
Fosinopril
The serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.
Fosphenytoin
The serum concentration of Tipranavir can be decreased when it is combined with Fosphenytoin.
Fusidate
The serum concentration of Tipranavir can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Tipranavir can be increased when it is combined with Fusidic Acid.
Galantamine
The metabolism of Galantamine can be decreased when combined with Tipranavir.
Garlic Allergenic Extract
The serum concentration of Tipranavir can be decreased when it is combined with Garlic.
Gefitinib
The metabolism of Gefitinib can be decreased when combined with Tipranavir.
Gemfibrozil
The metabolism of Tipranavir can be decreased when combined with Gemfibrozil.
Genistein
Genistein may increase the dermatologic adverse activities of Tipranavir.
Gestodene
The serum concentration of Gestodene can be increased when it is combined with Tipranavir.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Tipranavir.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Tipranavir.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tipranavir.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Tipranavir.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Tipranavir.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Tipranavir.
Granisetron
The metabolism of Granisetron can be decreased when combined with Tipranavir.
Halofantrine
The metabolism of Halofantrine can be decreased when combined with Tipranavir.
Haloperidol
The metabolism of Haloperidol can be decreased when combined with Tipranavir.
Halothane
The metabolism of Halothane can be decreased when combined with Tipranavir.
Heparin
Tipranavir may increase the anticoagulant activities of Heparin.
Hydrocodone
The serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.
HYDROCODONE POLISTIREX
The serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.
Hydromorphone
The metabolism of Hydromorphone can be decreased when combined with Tipranavir.
Hydroxytyrosol
Tipranavir may increase the antiplatelet activities of Hydroxytyrosol.
Hypoxis hemerocallidea root extract
The serum concentration of Tipranavir can be decreased when it is combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Tipranavir.
Icosapent Ethyl
Tipranavir may increase the antiplatelet activities of Icosapent ethyl.
Idarubicin
The metabolism of Idarubicin can be decreased when combined with Tipranavir.
Idelalisib
The metabolism of Tipranavir can be decreased when combined with Idelalisib.
Ifenprodil
Tipranavir may increase the antiplatelet activities of Ifenprodil.
Iloperidone
The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Tipranavir.
Iloprost
Tipranavir may increase the antiplatelet activities of Iloprost.
Imatinib
The metabolism of Imatinib can be decreased when combined with Tipranavir.
Imidapril
The serum concentration of Imidapril can be decreased when it is combined with Tipranavir.
Imipramine
The metabolism of Imipramine can be decreased when combined with Tipranavir.
Indinavir
The serum concentration of Indinavir can be decreased when it is combined with Tipranavir.
INDINAVIR ANHYDROUS
The serum concentration of Indinavir can be decreased when it is combined with Tipranavir.
Indobufen
Tipranavir may increase the antiplatelet activities of Indobufen.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Tipranavir.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tipranavir.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Tipranavir.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tipranavir.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tipranavir.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tipranavir.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tipranavir.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tipranavir.
Ipratropium Bromide
The metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.
Ipratropium Bromide Anhydrous
The metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.
Isavuconazole
The serum concentration of Tipranavir can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Tipranavir can be decreased when combined with Isavuconazonium.
Isoflurophate
The serum concentration of Isoflurophate can be decreased when it is combined with Tipranavir.
Isoniazid
The metabolism of Tipranavir can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Tipranavir can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Itraconazole can be increased when it is combined with Tipranavir.
Ivacaftor
The serum concentration of Tipranavir can be increased when it is combined with Ivacaftor.
Ixazomib
The serum concentration of Ixazomib can be decreased when it is combined with Tipranavir.
Ketanserin
Tipranavir may increase the antiplatelet activities of Ketanserin.
Ketoconazole
The serum concentration of Ketoconazole can be increased when it is combined with Tipranavir.
Labetalol
The metabolism of Labetalol can be decreased when combined with Tipranavir.
Lansoprazole
The serum concentration of Lansoprazole can be decreased when it is combined with Tipranavir.
Lepirudin
Tipranavir may increase the anticoagulant activities of Lepirudin.
Letermovir
The metabolism of Letermovir can be decreased when combined with Tipranavir.
Levodopa
The metabolism of Levodopa can be decreased when combined with Tipranavir.
Levomilnacipran
The metabolism of Levomilnacipran can be decreased when combined with Tipranavir.
Levonorgestrel
The serum concentration of Levonorgestrel can be increased when it is combined with Tipranavir.
Lidocaine
The metabolism of Lidocaine can be decreased when combined with Tipranavir.
Linagliptin
The serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Tipranavir.
Lisinopril
The serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.
Lisinopril Anhydrous
The serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Tipranavir.
Lomitapide
The serum concentration of Lomitapide can be increased when it is combined with Tipranavir.
Lomustine
The metabolism of Lomustine can be decreased when combined with Tipranavir.
Loperamide
The metabolism of Loperamide can be decreased when combined with Tipranavir.
Lopinavir
The serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.
Loratadine
The metabolism of Loratadine can be decreased when combined with Tipranavir.
Lorcaserin
The metabolism of Lorcaserin can be decreased when combined with Tipranavir.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Tipranavir.
Luliconazole
The serum concentration of Tipranavir can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Tipranavir can be decreased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Tipranavir can be decreased when combined with Lumefantrine.
Lynestrenol
The serum concentration of Lynestrenol can be increased when it is combined with Tipranavir.
Manidipine
The metabolism of Tipranavir can be decreased when combined with Manidipine.
Maprotiline
The metabolism of Maprotiline can be decreased when combined with Tipranavir.
Medroxyprogesterone Acetate
The serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Tipranavir.
Meperidine
The risk or severity of adverse effects can be increased when Tipranavir is combined with Pethidine.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Tipranavir.
Mequitazine
The serum concentration of Mequitazine can be increased when it is combined with Tipranavir.
Mesoridazine
The metabolism of Mesoridazine can be decreased when combined with Tipranavir.
Mestranol
Mestranol may increase the dermatologic adverse activities of Tipranavir.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Tipranavir.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.
Methadone
The serum concentration of Methadone can be decreased when it is combined with Tipranavir.
Methamphetamine
The metabolism of Methamphetamine can be decreased when combined with Tipranavir.
Methotrimeprazine
The metabolism of Tipranavir can be decreased when combined with Methotrimeprazine.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Tipranavir.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tipranavir.
Methylphenidate
The metabolism of Methylphenidate can be decreased when combined with Tipranavir.
Methyprylon
The metabolism of Methyprylon can be decreased when combined with Tipranavir.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Tipranavir.
Metoclopramide
The metabolism of Metoclopramide can be decreased when combined with Tipranavir.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Tipranavir.
Metronidazole
The risk or severity of adverse effects can be increased when Metronidazole is combined with Tipranavir.
Mexiletine
The metabolism of Mexiletine can be decreased when combined with Tipranavir.
Mianserin
The metabolism of Mianserin can be decreased when combined with Tipranavir.
Midazolam
The serum concentration of Midazolam can be increased when it is combined with Tipranavir.
Midostaurin
The metabolism of Tipranavir can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Tipranavir can be increased when it is combined with Mifepristone.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Tipranavir.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Tipranavir.
Milrinone
Tipranavir may increase the antiplatelet activities of Milrinone.
Minaprine
The metabolism of Minaprine can be decreased when combined with Tipranavir.
Mirabegron
The metabolism of Mirabegron can be decreased when combined with Tipranavir.
Mirtazapine
The metabolism of Mirtazapine can be decreased when combined with Tipranavir.
Mitotane
The serum concentration of Tipranavir can be decreased when it is combined with Mitotane.
Moclobemide
The metabolism of Moclobemide can be decreased when combined with Tipranavir.
Modafinil
The metabolism of Tipranavir can be decreased when combined with Modafinil.
Moexipril
The serum concentration of Moexipril can be decreased when it is combined with Tipranavir.
Morphine
The metabolism of Morphine can be decreased when combined with Tipranavir.
Nadroparin
Tipranavir may increase the anticoagulant activities of Nadroparin.
Nateglinide
The metabolism of Nateglinide can be decreased when combined with Tipranavir.
Nebivolol
The serum concentration of Nebivolol can be increased when it is combined with Tipranavir.
Nefazodone
The serum concentration of Nefazodone can be increased when it is combined with Tipranavir.
Nelfinavir
The serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir.
Netupitant
The serum concentration of Tipranavir can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Nevirapine can be increased when it is combined with Tipranavir.
Nicardipine
The metabolism of Nicardipine can be decreased when combined with Tipranavir.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Tipranavir.
Nicotine
The metabolism of Nicotine can be decreased when combined with Tipranavir.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Tipranavir.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Tipranavir.
Nilotinib
The metabolism of Tipranavir can be decreased when combined with Nilotinib.
Nimesulide
Tipranavir may increase the antiplatelet activities of Nimesulide.
Nitrofurazone
The metabolism of Nitrofural can be decreased when combined with Tipranavir.
Norelgestromin
The serum concentration of Norelgestromin can be increased when it is combined with Tipranavir.
Norgestimate
The serum concentration of Norgestimate can be increased when it is combined with Tipranavir.
Norgestrel
The serum concentration of Norgestrel can be increased when it is combined with Tipranavir.
Nortriptyline
The metabolism of Nortriptyline can be decreased when combined with Tipranavir.
O-PHENANTHROLINE
The serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Tipranavir.
Olanzapine
The metabolism of Olanzapine can be decreased when combined with Tipranavir.
Olaparib
The metabolism of Tipranavir can be decreased when combined with Olaparib.
Omeprazole
The serum concentration of Omeprazole can be decreased when it is combined with Tipranavir.
Ondansetron
The metabolism of Ondansetron can be decreased when combined with Tipranavir.
Opipramol
The serum concentration of Opipramol can be increased when it is combined with Tipranavir.
Opium
The metabolism of Opium can be decreased when combined with Tipranavir.
Osimertinib
The serum concentration of Tipranavir can be increased when it is combined with Osimertinib.
Oxycodone
The metabolism of Oxycodone can be decreased when combined with Tipranavir.
Oxymorphone
The metabolism of Oxymorphone can be decreased when combined with Tipranavir.
Palbociclib
The serum concentration of Tipranavir can be increased when it is combined with Palbociclib.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Tipranavir.
Panobinostat
The serum concentration of Tipranavir can be increased when it is combined with Panobinostat.
Pantoprazole
The serum concentration of Pantoprazole can be decreased when it is combined with Tipranavir.
Paregoric
The metabolism of Morphine can be decreased when combined with Tipranavir.
Paroxetine
The metabolism of Tipranavir can be decreased when combined with Paroxetine.
Pazopanib
The metabolism of Pazopanib can be decreased when combined with Tipranavir.
Peginterferon Alfa-2b
The serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.
Pentaerythritol Tetranitrate
Tipranavir may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentamidine
The metabolism of Pentamidine can be decreased when combined with Tipranavir.
Pentobarbital
The serum concentration of Pentobarbital can be increased when it is combined with Tipranavir.
Pentosan Polysulfate
Tipranavir may increase the anticoagulant activities of Pentosan Polysulfate.
Pentoxifylline
Tipranavir may increase the antiplatelet activities of Pentoxifylline.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Tipranavir.
Perhexiline
The metabolism of Perhexiline can be decreased when combined with Tipranavir.
Perindopril
The serum concentration of Perindopril can be decreased when it is combined with Tipranavir.
Perphenazine
The metabolism of Perphenazine can be decreased when combined with Tipranavir.
Phenacetin
The metabolism of Phenacetin can be decreased when combined with Tipranavir.
Phenformin
The metabolism of Phenformin can be decreased when combined with Tipranavir.
Phenindione
Tipranavir may increase the anticoagulant activities of Phenindione.
Phenobarbital
The serum concentration of Tipranavir can be decreased when it is combined with Phenobarbital.
Phenprocoumon
Tipranavir may increase the anticoagulant activities of Phenprocoumon.
Phenytoin
The serum concentration of Tipranavir can be decreased when it is combined with Phenytoin.
Pimozide
The serum concentration of Pimozide can be increased when it is combined with Tipranavir.
Pindolol
The metabolism of Pindolol can be decreased when combined with Tipranavir.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tipranavir.
Piperazine
The metabolism of Piperazine can be decreased when combined with Tipranavir.
Pipothiazine
The metabolism of Pipotiazine can be decreased when combined with Tipranavir.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Tipranavir.
Polyestradiol Phosphate
Polyestradiol phosphate may increase the dermatologic adverse activities of Tipranavir.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Tipranavir.
Posaconazole
The metabolism of Tipranavir can be decreased when combined with Posaconazole.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Tipranavir.
Prasugrel
Tipranavir may increase the antiplatelet activities of Prasugrel.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Tipranavir.
Primidone
The serum concentration of Primidone can be increased when it is combined with Tipranavir.
Procainamide
The metabolism of Procainamide can be decreased when combined with Tipranavir.
Prochlorperazine
The metabolism of Prochlorperazine can be decreased when combined with Tipranavir.
Progesterone
The metabolism of Progesterone can be decreased when combined with Tipranavir.
Promazine
The metabolism of Tipranavir can be decreased when combined with Promazine.
Promestriene
Promestriene may increase the dermatologic adverse activities of Tipranavir.
Promethazine
The metabolism of Promethazine can be decreased when combined with Tipranavir.
Propafenone
The serum concentration of Propafenone can be increased when it is combined with Tipranavir.
Propofol
The metabolism of Propofol can be decreased when combined with Tipranavir.
Propranolol
The metabolism of Propranolol can be decreased when combined with Tipranavir.
protein C, human
Tipranavir may increase the anticoagulant activities of Protein C.
protein S, human
Tipranavir may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Tipranavir may increase the anticoagulant activities of Protocatechualdehyde.
Protriptyline
The metabolism of Protriptyline can be decreased when combined with Tipranavir.
Pseudoephedrine
The metabolism of Pseudoephedrine can be decreased when combined with Tipranavir.
Quetiapine
The metabolism of Quetiapine can be decreased when combined with Tipranavir.
Quetiapine fumarate
The metabolism of Quetiapine can be decreased when combined with Tipranavir.
Quinapril
The serum concentration of Quinapril can be decreased when it is combined with Tipranavir.
Quinestrol
Quinestrol may increase the dermatologic adverse activities of Tipranavir.
Quinidine
The serum concentration of Quinidine can be increased when it is combined with Tipranavir.
Quinine
The metabolism of Quinine can be decreased when combined with Tipranavir.
Rabeprazole
The serum concentration of Rabeprazole can be decreased when it is combined with Tipranavir.
Racecadotril
The serum concentration of Racecadotril can be decreased when it is combined with Tipranavir.
Raltegravir
The serum concentration of Raltegravir can be decreased when it is combined with Tipranavir.
Ramipril
The serum concentration of Ramipril can be decreased when it is combined with Tipranavir.
Ranitidine
The metabolism of Ranitidine can be decreased when combined with Tipranavir.
Ranolazine
The metabolism of Tipranavir can be decreased when combined with Ranolazine.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Tipranavir.
Remoxipride
The metabolism of Remoxipride can be decreased when combined with Tipranavir.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tipranavir.
Resveratrol
Tipranavir may increase the antiplatelet activities of Resveratrol.
Reviparin
Tipranavir may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Tipranavir may increase the anticoagulant activities of Reviparin.
Rifabutin
The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Tipranavir.
Rifampin
The serum concentration of Tipranavir can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Rifapentine can be increased when it is combined with Tipranavir.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Tipranavir.
Riociguat
The serum concentration of Riociguat can be increased when it is combined with Tipranavir.
Risperidone
The metabolism of Risperidone can be decreased when combined with Tipranavir.
Ritonavir
The serum concentration of Ritonavir can be decreased when it is combined with Tipranavir.
Rivaroxaban
The serum concentration of Rivaroxaban can be decreased when it is combined with Tipranavir.
Rolapitant
The metabolism of Tipranavir can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Tipranavir can be decreased when combined with Ropinirole.
Ropivacaine
The metabolism of Ropivacaine can be decreased when combined with Tipranavir.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tipranavir.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Tipranavir.
Rotigotine
The metabolism of Rotigotine can be decreased when combined with Tipranavir.
Rucaparib
The metabolism of Rucaparib can be decreased when combined with Tipranavir.
Salmeterol
The serum concentration of Salmeterol can be increased when it is combined with Tipranavir.
Saquinavir
The serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.
Saquinavir Mesylate
The serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.
Sarilumab
The therapeutic efficacy of Tipranavir can be decreased when used in combination with Sarilumab.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Tipranavir.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Tipranavir.
Sertindole
The metabolism of Sertindole can be decreased when combined with Tipranavir.
Sertraline
The metabolism of Sertraline can be decreased when combined with Tipranavir.
Sevoflurane
Tipranavir may increase the antiplatelet activities of Sevoflurane.
Sildenafil
The serum concentration of Sildenafil can be increased when it is combined with Tipranavir.
Siltuximab
The serum concentration of Tipranavir can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Simeprevir can be decreased when it is combined with Tipranavir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Tipranavir.
Sitagliptin
The serum concentration of Sitagliptin can be decreased when it is combined with Tipranavir.
Sitagliptin Phosphate
The serum concentration of Sitagliptin can be decreased when it is combined with Tipranavir.
Spirapril
The serum concentration of Spirapril can be decreased when it is combined with Tipranavir.
ST. JOHN'S WORT EXTRACT
The serum concentration of Tipranavir can be decreased when it is combined with St. John's Wort.
Sulfisoxazole
The metabolism of Tipranavir can be decreased when combined with Sulfisoxazole.
synthetic conjugated estrogens, A
Synthetic Conjugated Estrogens, A may increase the dermatologic adverse activities of Tipranavir.
synthetic conjugated estrogens, B
Synthetic Conjugated Estrogens, B may increase the dermatologic adverse activities of Tipranavir.
Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Tipranavir.
Tadalafil
The serum concentration of Tadalafil can be increased when it is combined with Tipranavir.
Tamoxifen
The serum concentration of Tamoxifen can be increased when it is combined with Tipranavir.
Tamsulosin
The serum concentration of Tamsulosin can be increased when it is combined with Tipranavir.
Tapentadol
The metabolism of Tapentadol can be decreased when combined with Tipranavir.
Tegaserod
The metabolism of Tegaserod can be decreased when combined with Tipranavir.
Telaprevir
The serum concentration of Telaprevir can be decreased when it is combined with Tipranavir.
Telithromycin
The metabolism of Tipranavir can be decreased when combined with Telithromycin.
Temsirolimus
The risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.
Tenofovir Disoproxil
The serum concentration of Tipranavir can be decreased when it is combined with Tenofovir disoproxil.
Terbinafine
The metabolism of Tipranavir can be decreased when combined with Terbinafine.
Terfenadine
The metabolism of Terfenadine can be decreased when combined with Tipranavir.
Tetrabenazine
The serum concentration of Tetrabenazine can be increased when it is combined with Tipranavir.
Theophylline
The metabolism of Theophylline can be decreased when combined with Tipranavir.
Theophylline anhydrous
The metabolism of Theophylline can be decreased when combined with Tipranavir.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Tipranavir.
Tianeptine
The serum concentration of Tianeptine can be increased when it is combined with Tipranavir.
Tibolone
Tibolone may increase the dermatologic adverse activities of Tipranavir.
Ticagrelor
Tipranavir may increase the antiplatelet activities of Ticagrelor.
Ticlopidine
Tipranavir may increase the antiplatelet activities of Ticlopidine.
Timolol
The metabolism of Timolol can be decreased when combined with Tipranavir.
Timolol Anhydrous
The metabolism of Timolol can be decreased when combined with Tipranavir.
Tiotropium
The metabolism of Tiotropium can be decreased when combined with Tipranavir.
Tirofiban
Tipranavir may increase the antiplatelet activities of Tirofiban.
Tocilizumab
The serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Tipranavir.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tipranavir.
Tolterodine
The metabolism of Tolterodine can be decreased when combined with Tipranavir.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Tipranavir.
Topiramate
The metabolism of Tipranavir can be decreased when combined with Topiramate.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Tipranavir.
Tramadol
The therapeutic efficacy of Tramadol can be decreased when used in combination with Tipranavir.
Trandolapril
The serum concentration of Trandolapril can be decreased when it is combined with Tipranavir.
Tranilast
Tipranavir may increase the antiplatelet activities of Tranilast.
Tranylcypromine
The metabolism of Tipranavir can be decreased when combined with Tranylcypromine.
Trapidil
Tipranavir may increase the antiplatelet activities of Trapidil.
Trazodone
The serum concentration of Trazodone can be increased when it is combined with Tipranavir.
Triazolam
The serum concentration of Triazolam can be increased when it is combined with Tipranavir.
Triflusal
Tipranavir may increase the antiplatelet activities of Triflusal.
Trimipramine
The metabolism of Trimipramine can be decreased when combined with Tipranavir.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Tipranavir.
Troxerutin
Tipranavir may increase the anticoagulant activities of Troxerutin.
Umeclidinium
The metabolism of Umeclidinium can be decreased when combined with Tipranavir.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Tipranavir.
Valproate
The serum concentration of Valproic Acid can be decreased when it is combined with Tipranavir.
Valproic Acid
The serum concentration of Valproic Acid can be decreased when it is combined with Tipranavir.
Vemurafenib
The serum concentration of Tipranavir can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Venlafaxine can be decreased when combined with Tipranavir.
Verapamil
The metabolism of Verapamil can be decreased when combined with Tipranavir.
Vilazodone
The metabolism of Vilazodone can be decreased when combined with Tipranavir.
Vildagliptin
The serum concentration of Vildagliptin can be decreased when it is combined with Tipranavir.
Vinblastine
The metabolism of Vinblastine can be decreased when combined with Tipranavir.
Vinorelbine
The metabolism of Vinorelbine can be decreased when combined with Tipranavir.
Vitamin E
The risk or severity of adverse effects can be increased when Tipranavir is combined with Vitamin E.
Vorapaxar
Tipranavir may increase the antiplatelet activities of Vorapaxar.
Voriconazole
The metabolism of Tipranavir can be decreased when combined with Voriconazole.
Vortioxetine
The serum concentration of Vortioxetine can be increased when it is combined with Tipranavir.
Warfarin
Tipranavir may increase the anticoagulant activities of Warfarin.
Yohimbine
The metabolism of Yohimbine can be decreased when combined with Tipranavir.
Zalcitabine
The metabolism of Zalcitabine can be decreased when combined with Tipranavir.
Zidovudine
The serum concentration of Zidovudine can be decreased when it is combined with Tipranavir.
Ziprasidone
The metabolism of Tipranavir can be decreased when combined with Ziprasidone.
Zofenopril
The serum concentration of Zofenopril can be decreased when it is combined with Tipranavir.
Zolpidem
The metabolism of Zolpidem can be decreased when combined with Tipranavir.
Zuclopenthixol
The metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.
